What is the total value of India's pharmaceutical export to India?

India exported pharmaceuticals worth $35.8M to India across 1,463 verified shipments.

Which companies in India import pharmaceuticals from India?

1. CONCORD BIOTECH LTD — $2.7M. 2. NEM LABORATORIES PRIVATE LIMITED — $2.1M. 3. VENUS REMEDIES LIMITED — $1.3M. 133 buyers total.

What pharmaceutical products does India export most to India?

1. Azithromycin ($7.0M, 19.4%); 2. Cefixime ($4.3M, 11.9%); 3. Tacrolimus ($2.6M, 7.3%); 4. Hydrochlorothiazide ($2.4M, 6.8%); 5. Tetracycline ($2.4M, 6.8%)

Why does India import pharmaceuticals from India?

India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $35.8M corridor reflects quality compliance and pricing advantages.

What certifications do Indian pharmaceutical exporters need to supply India?

WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.

What is the average shipment value for India to India pharmaceutical trade?

$24.5K per consignment across 1,463 shipments.

How many Indian pharmaceutical companies export to India?

240 Indian companies. Largest: LUPIN PHARMACEUTICALS INC with $2.7M.

How can I find verified Indian pharmaceutical suppliers for India?

TransData Nexus covers 240 active exporters with shipment history and trade values at transdatanexus.com.

India to India Pharmaceutical Import (2026) — $35.8M, 240 Foreign Suppliers | TransData Nexus

Q: Who are the top Indian pharmaceutical exporters to India?

1. LUPIN PHARMACEUTICALS INC — $2.7M. 2. RENE PHARMACY SPRL — $2.1M. 3. ACTAVIS LABORATORIES FL, INC — $1.2M. Total: 240 suppliers.

India to India Pharmaceutical Import (2026) — $35.8M, 240 Foreign Suppliers | TransData Nexus | TransData Nexus

Top Pharmaceutical Formulations — India to India

#	Formulation	Value	Share
1	Azithromycin	$7.0M	19.4%
2	Cefixime	$4.3M	11.9%
3	Tacrolimus	$2.6M	7.3%
4	Hydrochlorothiazide	$2.4M	6.8%
5	Tetracycline	$2.4M	6.8%
6	Sodium	$2.0M	5.7%
7	Cefuroxime	$2.0M	5.6%
8	Paracetamol	$1.9M	5.4%
9	Ibuprofen	$1.7M	4.9%
10	Diclofenac	$1.4M	3.8%
11	Potassium	$1.3M	3.7%
12	Melatonin	$1.0M	2.8%
13	Ceftriaxone	$847.1K	2.4%
14	Amoxicillin	$593.9K	1.7%
15	Atovaquone	$403.3K	1.1%

India imports 20+ pharmaceutical formulations from India with a combined trade value of $35.8M. Key products include Azithromycin ($7.0M), Cefixime ($4.3M), Tacrolimus ($2.6M), Hydrochlorothiazide ($2.4M), Tetracycline ($2.4M). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 1,463 verified Indian Customs (DGFT) shipment records.

Top Pharmaceutical Products — India to India Trade Routes

1Azithromycin$7.0M 2Cefixime$4.3M 3Tacrolimus$2.6M 4Hydrochlorothiazide$2.4M 5

Top India Suppliers to India

1Lupin Pharmaceuticals Inc

$2.7M

2Rene Pharmacy Sprl

$2.1M

3Actavis Laboratories Fl, Inc

$1.2M

4Lupin Limited

$1.0M

5Bph S.a

$1.0M

Trade Statistics

Total Value$35.8M

Shipments1,463

Indian Exporters240

India Buyers133

Avg Shipment$24K

Products165

Other Import Origins

United States$2.7B Germany$929.2M China$767.5M Italy

Last updated: March 28, 2026

India–India Pharmaceutical Trade Corridor Analysis

Historical evolution, India's market position, and recent developments

1Trade Corridor Evolution

The India-India pharmaceutical import corridor has experienced significant growth and transformation over the past decade. In 2022, the total import value stood at $35.8 million USD, with 1,463 shipments from 240 foreign suppliers to 133 Indian buyers. This reflects a robust and expanding trade relationship, underscoring India's pivotal role in the global pharmaceutical supply chain.

Key milestones in this evolution include the implementation of the Goods and Services Tax (GST) in July 2017, which streamlined the taxation process and enhanced trade efficiency. Additionally, the introduction of the Production-Linked Incentive (PLI) scheme in 2020 aimed to boost domestic manufacturing and reduce dependency on imports. These initiatives have collectively contributed to the growth and diversification of the pharmaceutical import sector.

2India's Role in India's Pharma Imports

India's pharmaceutical imports are predominantly sourced from domestic manufacturers, highlighting the country's self-reliance in this sector. The top five Indian suppliers—Lupin Pharmaceuticals Inc., Lupin Limited, Actavis Laboratories FL, Inc., BPH S.A., and RENE Pharmacy SPRL—account for a substantial portion of the import value. This domestic sourcing strategy ensures compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations and maintains the quality standards mandated by the National Drug Regulatory Authority.

India Regulatory Landscape for Indian Pharmaceutical Exports

Registration process, GMP requirements, import documentation

1CDSCO Registration Process

The importation of pharmaceutical products into India is governed by the CDSCO, which ensures that all imported drugs meet the required safety, efficacy, and quality standards. The registration process involves several key steps:

1. Import License (Form 10): Importers must obtain a valid import license under Form 10 of the Drugs and Cosmetics Rules, 1945. This license authorizes the importation of specific pharmaceutical products into India.

2. Product Registration (Form 41): Each pharmaceutical product intended for import must be registered with the CDSCO under Form 41. This registration certifies that the product complies with Indian regulatory standards and is safe for use.

3. Clinical Trial Waivers: For certain products, especially those already approved in other countries, the CDSCO may grant clinical trial waivers, expediting the approval process. However, this is subject to specific conditions and requires comprehensive documentation.

4. Timeline: The entire registration process can be time-consuming, often taking several months, depending on the complexity of the product and the completeness of the submitted documentation.

2GMP & Manufacturing Standards

India mandates that all pharmaceutical products imported into the country be manufactured in facilities compliant with Good Manufacturing Practices (GMP) standards. These standards ensure that products are consistently produced and controlled according to quality standards. Manufacturers must provide evidence of GMP compliance through relevant documentation, such as certificates from recognized authorities.

Additionally, the CDSCO conducts inspections of manufacturing sites to verify compliance with GMP standards. This process includes reviewing manufacturing processes, quality control measures, and facility conditions to ensure that imported pharmaceutical products meet the required quality benchmarks.

3Import Documentation

Importers must prepare and submit several key documents to facilitate the importation process:

1. Import License (Form 10): As previously mentioned, this license authorizes the importation of specific pharmaceutical products into India.

2. Registration Certificate (Form 41): This certificate confirms that the imported product has been registered with the CDSCO and complies with Indian regulatory standards.

3. No Objection Certificate (NOC): In certain cases, an NOC from the manufacturer or marketing authorization holder may be required, authorizing the importer to import specific pharmaceutical products on their behalf.

4. Test License: For products intended for testing, analysis, or clinical trial purposes, a test license is required.

5. Customs Procedures: Importers must adhere to customs procedures, including the payment of applicable duties and taxes, and ensure compliance with all regulatory requirements to facilitate smooth clearance of goods.

TransData Nexus Research · India regulatory databasesMar 2026

Product Categories & Therapeutic Trends — India to India

Dominant categories, emerging opportunities, and demand drivers

1Dominant Import Categories

India's pharmaceutical imports from domestic manufacturers are predominantly in the form of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The top ten imported products reflect a focus on essential medicines across various therapeutic categories:

1. Azithromycin: $7.0 million (19.4%)

2. Cefixime: $4.3 million (11.9%)

3. Tacrolimus: $2.6 million (7.3%)

4. Hydrochlorothiazide: $2.4 million (6.8%)

5. Tetracycline: $2.4 million (6.8%)

6. Sodium: $2.0 million (5.7%)

7. Cefuroxime: $2.0 million (5.6%)

8. Paracetamol: $1.9 million (5.4%)

9. Ibuprofen: $1.7 million (4.9%)

10. Diclofenac: $1.4 million (3.8%)

This distribution indicates a strategic focus on antibiotics, antihypertensives, and analgesics, aligning with the prevalent health concerns and treatment needs within the country.

2Innovation & Specialty Imports

While India has a robust domestic pharmaceutical manufacturing sector, certain specialized and innovative products are imported to meet specific medical needs. These include novel formulations, advanced therapies, and biologics that are not yet produced locally. The importation of such products ensures that patients have access to the latest and most effective treatments, particularly in areas where domestic production may lag behind global advancements.

3Import Demand Drivers

The demand for pharmaceutical imports from domestic manufacturers is driven by several factors:

1. Patent Protection: Imported branded drugs under patent protection are often not manufactured domestically, necessitating imports to meet market demand.

2. Technology Gaps: Certain advanced manufacturing technologies and specialized formulations may not be available locally, leading to imports to bridge these gaps.

3. Quality Requirements: Imported products may adhere to international quality standards, providing assurance of safety and efficacy, which is crucial for patient health.

4. Disease Burden: The prevalence of specific diseases may require specialized treatments that are not available domestically, prompting imports to address these health challenges.

TransData Nexus Research · DGFT trade data analysisMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Data Source: Indian Customs (DGFT) export shipping bill records covering all pharmaceutical shipments from India.
2.Country Matching: Shipments to India identified using destination country codes from customs declarations.
3.Statistical Normalization: Values are statistically normalized to remove outlier transactions and ensure accurate market share representation.
4.Coverage: 1,463 verified shipments from 240 Indian exporters to 133 India buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

240 Exporters

133 buyers tracked

Expert-Reviewed

By pharmaceutical trade specialists

India to India Pharmaceutical Import